A case of deep vein thrombosis in idiopathic nephrotic syndrome wit resistance to activated protein C

Journal of Nephrology

Volumn 11, Issue 2, 1998, Pages 76-77

  Campisi, Salvatore ^a,b   Cavatorta, Fosco ^a  

^a General Hospital   (Italy)

^b General Hosptial ^*  (Italy)

Author keywords

Deep vein thrombosis; Factor V Leiden; Nephrotic syndrome; Thrombophilia

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; HEPARIN; WARFARIN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ANTICOAGULATION; ARTICLE; CASE REPORT; DEEP VEIN THROMBOSIS; FAMILIAL DISEASE; HUMAN; IDIOPATHIC DISEASE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEPHROTIC SYNDROME; ORAL DRUG ADMINISTRATION; THROMBOPHILIA;

ADULT; ANTICOAGULANTS; FACTOR V; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW-UP STUDIES; HEPARIN; HUMANS; MALE; METHYLPREDNISOLONE; NEPHROTIC SYNDROME; POINT MUTATION; PROTEIN C; THROMBOPHILIA; THROMBOPHLEBITIS; WARFARIN;

EID: 0031956811     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Llach F. Hypercoagulability, renal vein thrombosis, and other thromboembolic complications of nephrotic syndrome. Kidney Int 1985; 28: 429-39.
2. Dahlback B. Inherited thombophilia: resistance to activated protein C as a pathogenetic factor of venous thromboembolism. Blood 1995; 85: 607-14.
3. Voorberg J, Roelse J, Koopman R et al. Association of idiopathic venous thromboembolism with single point-mutation of Arg506 of factor V. Lancet 1994; 343: 1535-6.
4. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C Proc Natl Acad Sci USA 1993; 90: 1004-8.
5. Koster T, Rosendaal FR, de Ronde H, Brief E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia Study. Lancer 1993; 342: 1503-6.
6. Simioni P, Prandoni P, Lensing A, et al. The risk of recurrent venous thromboembolism in patients with AN Arg506 GIn mutation in the gene for factor V (Factor V Leiden). N Eng J Med 1997; 336; 399-403.
7. Bertina RM, Koeleman B, Koster T, et al. Nature 1994; 369: 64-7.
8. Commento Editoriale. Una nuova causa di trombofilia. Ann Ital Med Int 11:5-7, 1996.
9. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis N Eng J Med 1994; 330: 517-22.
10. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisneberg PR, Miletich J. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men N Eng J Med 1995; 332: 912-9.
11. Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-5.
12. Den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as risk factor for deep-vein-thrombosis. N Eng J Med 1996; 334: 759-62.
13. Mandel H, Brenner B, Berani M, et al. Coexistence of hereditary homocystinuria and factor V Leiden-Effect on thrombosis. N Engl J Med 1996; 334: 763-8.
14. Gandrille S, Greengard JS, Alhene Gelas M. Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C deficient patients. Blood 1995; 86: 219-24.
15. Sarasin FP, Schifferli JA. Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int 1994; 45: 578-85.